681004-49-9

Basic information

• Product Name: 1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine
• Synonyms: 1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine;1-METHYL-4-(2-METHYL-4-NITROPHENYL)PIPERAZINE(WXC06660)
• CAS NO: 681004-49-9
• Molecular Formula: C₁₂H₁₇N₃O₂
• Molecular Weight: 235.28228
• Mol File: 681004-49-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine(681004-49-9)
• EPA Substance Registry System: 1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine(681004-49-9)

Safety Data

• Hazardous Substances Data: 681004-49-9(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine is used as a potential drug candidate for various therapeutic applications due to its unique chemical structure and the possibility of interacting with specific biological targets.
Used in Pharmacological Research:
In the field of pharmacological research, 1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine is used as a valuable chemical for studying its interactions with target proteins, which can lead to the development of new drugs with novel mechanisms of action.
Used in Central Nervous System Agents Development:
Due to its piperazine structure, 1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine is used as a target for the development of central nervous system agents, potentially offering new treatment options for neurological and psychiatric disorders.
Used in Scientific Research and Drug Development:
1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine's properties and potential applications make 1-Methyl-4-(2-Methyl-4-nitrophenyl)piperazine a valuable asset in scientific research and the advancement of drug development, contributing to the discovery of innovative therapeutics.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 455-88-9 5-nitro-2-fluorotoluene 

Downstream Products

• 1042433-27-1 2-[[5-cyano-2-[3-methyl-4-(4-methylpiperazin-1-yl)aniline]pyrimidin-4-yl]amino]benzamide 
• 681004-50-2 3-methyl-4-(4-methylpiperazin-1-yl)aniline 

Relevant articles and documents

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)

Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c-KIT/PDGFRα dual inhibitor, compound 31, with single-digit nanomolar potency against c-KIT and PDGFRα. Compared to Imatinib (1), 31 showed better antiproliferative efficacy against various TEL-c-KIT/PDGFRα-BaF3 isogenic cells, including three 1-resistant BaF3 cell lines, as well as against GIST-T1 and GIST-882 cell lines. Furthermore, compound 31 showed a good KinomeScan selectivity (468 kinases) (S score (1) = 0.01 at 1 μM concentration), good metabolic stability in liver microsomes, and no hERG inhibitory activity. It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors

A series of 2,4 diamino-pyrimidines have been identified from an analysis of open access high throughput anti-malarial screening data reported by GlaxoSmithKline at the 3D7 and resistant Dd2 strains. SAR expansion has been performed using structural knowledge of the most plausible parasite target. Seventeen new analogs have been synthesized and tested against the resistant K1 strain of Plasmodium falciparum (Pf). The cytotoxicity of the compounds was assessed in Vero and A549?cells and their selectivity towards human kinases including JAK2 and EGFR were undertaken. We identified compound 5n and 5m as sub-micromolar inhibitors, with equivalent anti-malarial activity to Chloroquine (CQ). Compounds 5d and 5k, μM inhibitors of Pf, displayed improved cytotoxicity with weak inhibition of the human kinases.

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

N-(3,4-disubstituted phenyl) salicylamide derivatives

A compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C